Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas

Neuro-Oncology

Volumn 15, Issue 9, 2013, Pages 1160-1172

  Xu, Shuo ^a,b   Shao, Qian Qian ^b   Sun, Jin Tang ^b   Yang, Ning ^a,b   Xie, Qi ^b   Wang, Dong Hai ^a,b   Huang, Qi Bing ^c   Huang, Bin ^a   Wang, Xin Yu ^a   Li, Xin Gang ^a   Qu, Xun ^b  

^a Institute of Basic Medical Sciences   (China)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

CD39 CD73 adenosinergic immunosuppression; glioma microenvironment; infiltrating T lymphocytes; malignant glioma; synergic effect

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5' NUCLEOTIDASE; BETA,GAMMA DIBROMOMETHYLENE 6 N,N DIETHYLADENOSINE TRIPHOSPHATE; CD39 ANTIGEN;

ARTICLE; CANCER PATIENT; CD4+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME ACTIVITY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HYDROLYSIS; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; PHENOTYPE;

CD39-CD73-ADENOSINERGIC IMMUNOSUPPRESSION; GLIOMA MICROENVIRONMENT; INFILTRATING T LYMPHOCYTES; MALIGNANT GLIOMA; SYNERGIC EFFECT;

5'-NUCLEOTIDASE; ADENOSINE; ANTIGENS, CD; APYRASE; BRAIN NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; GLIOMA; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTES, TUMOR-INFILTRATING;

EID: 84883192286     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not067     Document Type: Article

References (53)

1. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012; 14(Suppl 5):v1-49.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492-507.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. (Pubitemid 40349501)
4. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advancesinneuro-oncology: the avenuetoacure for malignant glioma. CA Cancer J Clin. 2010;60(3):166-193.
5. Heimberger AB, Sampson JH. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol. 2011;13(1):3-13.
6. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012; 62(5):309-335.
7. Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 2001;61(3):842-847. (Pubitemid 32175145)
8. De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblasto-ma multiforme. Clin Cancer Res. 2008;14(10):3098-3104.
9. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolongd progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblas-toma. J Clin Oncol. 2010;28(31):4722-4729.
10. Albesiano E, Han JE, Lim M. Mechanisms of local immunoresistance in glioma. Neurosurg Clin N Am. 2010;21(1):17-29.
11. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66(6):3294-3302.
12. Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene. 2010;29(39):5346-5358.
13. Yegutkin GG. Nucleotide-and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta. 2008;1783(5):673-694.
14. Ernst PB, Garrison JC, Thompson LF. Much ado about adenosine: adeno-sine synthesis and function in regulatory T cell biology. J Immunol. 2010;185(4):1993-1998.
15. Hasko G, Pacher P. Regulation of macrophage function by adenosine. Arterioscler Thromb Vasc Biol. 2012;32(4):865-869.
16. Zarek PE, Huang CT, Lutz ER, et al. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood. 2008;111(1):251-259.
17. Bastid J, Cottalorda-Regairaz A, Alberici G, Bonnefoy N, Eliaou JF, Bensussan A. ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene. 2012;32(14):1743-1751.
18. Jin D, Fan J, Wang L, et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 2010;70(6):2245-2255.
19. Stagg J, Divisekera U, McLaughlin N, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A. 2010;107(4):1547-1552.
20. Stagg J, Divisekera U, Duret H, et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 2011;71(8):2892-2900.
21. Wink MR, Lenz G, Braganhol E, et al. Altered extracellular ATP, ADP and AMP catabolism in glioma cell lines. Cancer Lett. 2003;198(2):211-218. (Pubitemid 37297794)
22. Morrone FB, Oliveira DL, Gamermann P, et al. Invivoglioblastomagrowth is reduced by apyrase activity in a rat glioma model. BMC Cancer. 2006;6:226.
23. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523-532.
24. Borsellino G, Kleinewietfeld M, Di Mitri D, et al. Expression of ectonucleo-tidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110(4):1225-1232. (Pubitemid 47281420)
25. Moncrieffe H, Nistala K, Kamhieh Y, et al. High expression of the ectonu-cleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory T cell population. J Immunol. 2010;185(1):134-143.
26. Schuler PJ, Schilling B, Harasymczuk M, et al. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients. Eur J Immunol. 2012;42(7):1876-1885.
27. Garcia-Hernandez MH, Portales-Cervantes L, Cortez-Espinosa N, et al. Expression andfunction ofP2X(7) receptor and CD39/Entpd1 in patients with type 2 diabetes and their association with biochemical parameters. Cell Immunol. 2011;269(2):135-143.
28. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401-404.
29. Braganhol E, Huppes D, Bernardi A, Wink MR, Lenz G, Battastini AM. A comparative study of ectonucleotidase and P2 receptor mRNA profiles in C6 cell line cultures and C6 ex vivo glioma model. Cell Tissue Res. 2009;335(2):331-340.
30. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of humanglioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 2006;8(3):261-279. (Pubitemid 46542651)
31. Mandapathil M, Hilldorfer B, Szczepanski MJ, et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem. 2010;285(10):7176-7186.
32. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008;14(16):5166-5172.
33. ′- nucleotidaseinhibitsplate-let aggregation. Arterioscler Thromb Vasc Biol. 2008;28(8):1477-1483.
34. Sun X, Wu Y, Gao W, et al. CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology. 2010;139(3):1030-1040.
35. Ndhlovu LC, Leal FE, Eccles-James IG, et al. A novel human CD4+ T-cell inducersubsetwithpotentimmunostimulatoryproperties.EurJImmunol. 2010;40(1):134-141.
36. Schuler PJ, Harasymczuk M, Schilling B, Lang S, Whiteside TL. Separation ofhuman CD4+CD39+ Tcellsbymagneticbeads revealstwophenotyp-ically and functionally different subsets. J Immunol Methods. 2011;369(1-2):59-68.
37. Zhou Q, Yan J, Putheti P, et al. Isolated CD39 expression on CD4+ Tcells denotes both regulatory and memory populations. Am J Transplant. 2009;9(10):2303-2311.
38. Sitkovsky MV, Kjaergaard J, Lukashev D, Ohta A. Hypoxia-adenosinergic immunosuppression:tumorprotectionbyTregulatorycells andcancerous tissue hypoxia. Clin Cancer Res. 2008;14(19):5947-5952.
39. Dwyer KM, Hanidziar D, Putheti P, et al. Expression of CD39 by human peripheralblood CD4+ CD25+ Tcellsdenotesaregulatorymemory phe-notype. Am J Transplant. 2010;10(11):2410-2420.
40. Hilchey SP, Kobie JJ, Cochran MR, et al. Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hypo-responsiveness. J Immunol. 2009;183(10):6157-6166.
41. Eltzschig HK, Kohler D, Eckle T, Kong T, Robson SC, Colgan SP. Centralrole of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood. 2009;113(1):224-232.
42. ′- nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest. 2002;110(7):993-1002.
43. Gorlach A. Control of adenosine transport by hypoxia. Circ Res. 2005;97(1):1-3. (Pubitemid 40982315)
44. Beavis PA, Stagg J, Darcy PK, Smyth MJ. CD73:apotent suppressorofan- titumor immune responses. Trends Immunol. 2012;33(5):231-237.
45. ′- ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells. J Cell Physiol. 2013;228(3):602-608.
46. Mills JH, Thompson LF, Mueller C, et al. CD73 isrequired for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. 2008;105(27):9325-9330.
47. ′-nucleotidase/CD73inU138MGgliomacelladhe- sion. Mol Cell Biochem. 2012;359(1-2):315-322.
48. Zhi X, Wang Y, Zhou X, et al. RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells. Cancer Sci. 2010;101(12):2561-2569.
49. Clayton A, Al-Taei S, Webber J, Mason MD, Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol. 2011;187(2):676-683.
50. Wang H, Lee S, Nigro CL, et al. NT5E (CD73)isepigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br J Cancer. 2012;106(8):1446-1452.
51. Serra S, Horenstein AL, Vaisitti T, et al. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood. 2011;118(23):6141-6152.
52. Stagg J, Beavis PA, Divisekera U, et al. CD73-deficient mice are resistant to carcinogenesis. Cancer Res. 2012;72(9):2190-2196.
53. Zhang B. CD73: a novel target for cancer immunotherapy. Cancer Res. 2010;70(16):6407-6411.